These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole. Reisner E; Arion VB; Guedes da Silva MF; Lichtenecker R; Eichinger A; Keppler BK; Kukushkin VY; Pombeiro AJ Inorg Chem; 2004 Nov; 43(22):7083-93. PubMed ID: 15500346 [TBL] [Abstract][Full Text] [Related]
25. Anticancer activity of hydrogen-bond-stabilized half-sandwich Ru(II) complexes with heterocycles. Mitra R; Das S; Shinde SV; Sinha S; Somasundaram K; Samuelson AG Chemistry; 2012 Sep; 18(39):12278-91. PubMed ID: 22903299 [TBL] [Abstract][Full Text] [Related]
26. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features. Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963 [TBL] [Abstract][Full Text] [Related]
27. Dimetallic Ru(II) arene complexes appended on bis-salicylaldimine induce cancer cell death and suppress invasion via p53-dependent signaling. Rahman FU; Bhatti MZ; Ali A; Duong HQ; Zhang Y; Ji X; Lin Y; Wang H; Li ZT; Zhang DW Eur J Med Chem; 2018 Sep; 157():1480-1490. PubMed ID: 30282320 [TBL] [Abstract][Full Text] [Related]
28. Osmium-arene complexes with high potency towards Mycobacterium tuberculosis. Coverdale JPC; Guy CS; Bridgewater HE; Needham RJ; Fullam E; Sadler PJ Metallomics; 2021 Apr; 13(4):. PubMed ID: 33693931 [TBL] [Abstract][Full Text] [Related]
29. Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands. Zhang Y; Zheng W; Luo Q; Zhao Y; Zhang E; Liu S; Wang F Dalton Trans; 2015 Aug; 44(29):13100-11. PubMed ID: 26106875 [TBL] [Abstract][Full Text] [Related]
30. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands. Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401 [TBL] [Abstract][Full Text] [Related]
31. Identification of clusters from reactions of ruthenium arene anticancer complex with glutathione using nanoscale liquid chromatography Fourier transform ion cyclotron mass spectrometry combined with (18)O-labeling. Wang F; Weidt S; Xu J; Mackay CL; Langridge-Smith PR; Sadler PJ J Am Soc Mass Spectrom; 2008 Apr; 19(4):544-9. PubMed ID: 18222094 [TBL] [Abstract][Full Text] [Related]
32. Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs. Ang WH; De Luca A; Chapuis-Bernasconi C; Juillerat-Jeanneret L; Lo Bello M; Dyson PJ ChemMedChem; 2007 Dec; 2(12):1799-806. PubMed ID: 17918761 [TBL] [Abstract][Full Text] [Related]
33. Picolinate ruthenium(II)-arene complex with in vitro antiproliferative and antimetastatic properties: comparison to a series of ruthenium(II)-arene complexes with similar structure. Gligorijević N; Aranđelović S; Filipović L; Jakovljević K; Janković R; Grgurić-Šipka S; Ivanović I; Radulović S; Tešić ZLj J Inorg Biochem; 2012 Mar; 108():53-61. PubMed ID: 22266461 [TBL] [Abstract][Full Text] [Related]